✦ LIBER ✦

Cumulative cost pattern comparison of prostate cancer treatments

✍ Scribed by Leslie S. Wilson; Ross Tesoro; Eric P. Elkin; Natalia Sadetsky; Jeanette M. Broering; David M. Latini; Janeen DuChane; Reema R. Mody; Peter R. Carroll

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 543 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22433

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost comparison of various treatment met

Cost comparison of various treatment methods for early prostate cancer

✍ Bharat B. Mittal 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 151 KB

The cost-effectiveness of alternative tr

The cost-effectiveness of alternative treatments in prostate cancer

✍ Paul Sperduto; Marilee Rose; Gail Jolitz; Sue Koering 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 120 KB

A comparison of the cost of various trea

A comparison of the cost of various treatment methods for early cancer of the prostate

✍ Gerald E. Hanks; Kathleen Dunlap 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 373 KB

Patterns of radiation treatment of elder

Patterns of radiation treatment of elderly patients with prostate cancer

✍ Gerald E. Hanks; Timothy E. Schultheiss; Alexandra Hanlon; Jean B. Owen 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 3 views

Background. The patterns of radiation care of elderly patients with prostate cancer treated with radiation therapy have not been described. As our population ages and screening increases the number of patients diagnosed, this becomes an important issue. Methods. The U.S. national surveys in prostat

Genetic pattern of prostate cancer progr

Genetic pattern of prostate cancer progression

✍ Tomo Saric; Zoran Brkanac; Dean A. Troyer; Susan S. Padalecki; Michael Sarosdy; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 71 KB 👁 2 views

Genetic alterations in primary prostate cancer (CaP) have been extensively studied, yet little is known about the genetic mechanisms underlying progression of primary CaP to metastatic prostate cancer. As a result, it is not possible to distinguish clinically indolent localized disease from potentia

Targeted treatment of prostate cancer

✍ Xinning Wang; Lihong Yin; Pravin Rao; Robert Stein; Kelley M. Harsch; Zhenghong 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

## Abstract Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer